Update on Investigational New Drugs

Update on Investigational New Drugs

Presenters

Joseph J. Eron, Jr, MD
University of North Carolina at Chapel Hill

Start

April 6, 2021 - 10:00 AM

End

April 6, 2021 - 11:15 AM

Add to iCal Calendar

Overview

Assessment of Needs

The IAS–USA offers this state-of-the-art activity as part of a nationwide continuing education effort for physicians on the evolving challenges of managing HIV disease. This webinar will discuss antiretroviral agents that are in clinical development (being given to participant with or with HIV) or late stage preclinical development and very likely to enter human trials. Additionally, this webinar will review mechanisms of action, antiretroviral activity, and information on adverse events and side effect. Lastly, it will discuss where these drugs may fit into treatment strategies for people with HIV for those agents in the later stage of clinical development.

Learning Objectives

On completion of this webinar, learners will be able to:

  • Describe steps in the virus life cycle that are targets for novel inhibitors of HIV replication
  • Discuss the results of recent clinical studies of investigational antiretroviral agents
  • Summarize how new antiretroviral agents may be used in the treatment of people living with HIV

Registration

Who Should Attend

This  webinar is designed for clinical decision makers who are actively involved in sexually transmitted infection care and research.

This activity is also relevant for registered nurses, pharmacists, and other health professionals.

Individual registration is required, even if you are viewing as a group, in order to receive continuing education credit or a certificate of participation.

Registration closes on Monday, April 5, 2021, 4:00 PM (PT).

Certificates will be available after the completion of the evaluation and claim form.

For more information or questions, please contact the registration department at registration@iasusa.org or 415-544-9400.

Conflicts of Interest

In the interest of maintaining the independence of its continuing education activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they or their spouses or partners have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the continuing education activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA continuing education activity.

The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Presenter Disclosure

Dr Eron has served as an ad hoc consultant to Janssen, ViiV Healthcare, Merck & Co, Inc, and Gilead Sciences, Inc. His institution receives contracts for clinical research on which Dr Eron is the local principal investigator from Janssen Therapeutics, ViiV Healthcare, and Gilead Sciences, Inc. (Updated 12/22/20)

All relevant financial relationships have been mitigated.

Continuing Education Credits

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Points

ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing Credits

These activities are eligible for ANCC credit, see final CNE activity announcement for specific details.

Pharmacy Credits

Accreditation Council for Pharmacy Education logo These activities are eligible for ACPE credit, see final CPE activity announcement for specific details.

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.

PLATINUM SUPPORTERS

Gilead Sciences, Inc
Merck & Co, Inc
ViiV Healthcare

SILVER SUPPORTER

Janssen Therapeutics

Frequently Asked Questions

View our list of FAQs about attending a webinar.

Further Questions?
Please contact the registration department at registration@iasusa.org or 415-544-9400.